29 October 2018 Revenue/EBITDA grew 27%/18% YoY to INR75,368m/INR8,802m. Adj. PAT grew 11% YoY to INR4,687m. For 2HFY19, we expect revenue growth of 25% YoY (similar to 1HFY19), but foresee increased pressure on margins (we expect contraction of 270bp) due to a spike in RM prices. Margins, however, took a sharp hit, primarily because of higher phos acid prices (USD758/MT v/s USD567 in 2QFY18). We expect continued margin headwinds, but revenue growth is likely to be supported by price hikes DAP prices already raised to INR29,000/MT (from INR26,600) and NPK price hike is planned from 1 November 2018. Given the price hikes and momentum in volume growth, we raise our revenue estimates for FY19/20 by 9%/8%. We value the stock at 20x FY20E EPS (~15% premium to its five-year average multiple), which is justified, in our view, given the likelihood to continued traction, revival in margins on phos acid plant commissioning, and a sustained RoE of 21%.